Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A histological "fly-through" of a diseased coronary artery.

Circulation. Cardiovascular imaging·2009

Same author

Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy.

JACC. Cardiovascular interventions·2009

Same author

The history of EuroPCR... and why a new journal?

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009

Same author

Treatment of de novo bifurcation lesions: comparison of Sirolimus- and Paclitaxel-eluting stents.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009

Same author

A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009

Same author

Intracoronary thermography: heat generation, transfer and detection.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009

Search research articles

Related Experiment Video

Updated: Jun 9, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Coronary stents: looking forward.

Scot Garg¹, Patrick W Serruys

¹Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.

Journal of the American College of Cardiology

|August 28, 2010

Summary

This summary is machine-generated.

Newer drug-eluting stents (DES) aim to improve long-term safety and reduce stent thrombosis. Biodegradable and polymer-free options show promising early results in ongoing trials.

More Related Videos

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

Related Experiment Videos

Last Updated: Jun 9, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

Area of Science:

Cardiovascular Devices
Biomaterials Science

Background:

Drug-eluting stents (DES) offer benefits but face long-term safety concerns, primarily stent thrombosis.
Addressing these concerns is crucial for advancing coronary artery interventions.

Purpose of the Study:

To review the current status of novel coronary stent technologies designed to overcome the limitations of existing DES.
To discuss emerging devices like biodegradable polymer DES, polymer-free DES, novel coated stents, fully biodegradable stents, bifurcation stents, and drug-eluting balloons.

Main Methods:

Review of pre-clinical and clinical trial data for new coronary stent technologies.
Analysis of emerging coronary devices including novel stent coatings and drug-eluting balloons.

Main Results:

Newer stent designs, including biodegradable polymer DES, polymer-free DES, and novel coatings, are under investigation.
Early results from pre-clinical and clinical trials for these advanced stents are promising.

Conclusions:

Ongoing research focuses on developing the ideal coronary stent with improved safety and efficacy profiles.
Novel coronary devices show potential to enhance treatment outcomes for coronary artery disease.